Dr. Reddy';s Laboratories Announces the Acquisition of an Injectable Product Portfolio from Eton Pharma
The portfolio includes the Biorphen® (phenylephrine hydrocholoride) Injection and Rezipres® (ephedrine hydrochloride) Injection NDAs with nine separate combinations of strengths and presentations and one first-to-file approved ANDA for Cysteine Hydrochloride for the
Under the terms of the agreement, Dr. Reddy’s acquired the Eton portfolio for an upfront payment of approximately
“Long before the COVID-19 pandemic, there have been concerns about access to some critical care products for hospitals and health systems. This acquisition provides our
The value of total addressable market for these products in the
*IQVIA Retail and Non-Retail MAT
RDY-0622-419
About Dr. Reddy’s: Dr. Reddy’s
Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers’, products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20220624005239/en/
INVESTOR RELATIONS
AMITA@DRREDDYS.COM
MEDIA RELATIONS
ushaiyer@drreddys.com
Source: Dr. Reddy’s